Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term NPC-12G gel in neurofibromatosis type 1
jRCT2051200032Active, not recruiting
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in neurofibromatosis type 1 (NF1), sponsored by Nobelpharma Co., Ltd. Primary endpoints: Discontinuation rates associated with adverse events and Adverse events leading to discontinuation. Started Jul 2020; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on jRCT2051200032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200032.